Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 6.95
(6.6%)
SEK 6.95
(6.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 321.5 Million SEK | 11.83% |
| 2022 | 287.49 Million SEK | -2.02% |
| 2021 | 293.42 Million SEK | 96.31% |
| 2020 | 149.47 Million SEK | 58.99% |
| 2019 | 94.01 Million SEK | 123.34% |
| 2018 | 42.09 Million SEK | 163.75% |
| 2017 | 15.96 Million SEK | 82.99% |
| 2016 | 8.72 Million SEK | 40.7% |
| 2015 | 6.19 Million SEK | 8.79% |
| 2014 | 5.69 Million SEK | 111.51% |
| 2013 | 2.69 Million SEK | 81660.24% |
| 2012 | 3295.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 77.22 Million SEK | 11.24% |
| 2024 Q2 | 61.89 Million SEK | -19.86% |
| 2023 Q4 | 69.42 Million SEK | 6.71% |
| 2023 Q1 | 66.08 Million SEK | 10.48% |
| 2023 Q2 | 69.79 Million SEK | 5.62% |
| 2023 FY | 317.46 Million SEK | 10.43% |
| 2023 Q3 | 65.05 Million SEK | -6.79% |
| 2022 Q1 | 93.17 Million SEK | 16.92% |
| 2022 Q2 | 64.85 Million SEK | -30.39% |
| 2022 FY | 287.49 Million SEK | -2.02% |
| 2022 Q3 | 69.65 Million SEK | 7.39% |
| 2022 Q4 | 59.81 Million SEK | -14.12% |
| 2021 Q1 | 47.53 Million SEK | -19.13% |
| 2021 Q4 | 79.69 Million SEK | -18.48% |
| 2021 Q3 | 97.75 Million SEK | 42.84% |
| 2021 Q2 | 68.43 Million SEK | 43.98% |
| 2021 FY | 293.42 Million SEK | 96.31% |
| 2020 FY | 149.47 Million SEK | 58.99% |
| 2020 Q1 | 28.78 Million SEK | -4.83% |
| 2020 Q3 | 34.44 Million SEK | 25.37% |
| 2020 Q4 | 58.77 Million SEK | 70.65% |
| 2020 Q2 | 27.47 Million SEK | -4.55% |
| 2019 FY | 94.01 Million SEK | 123.34% |
| 2019 Q4 | 30.24 Million SEK | 32.45% |
| 2019 Q3 | 22.83 Million SEK | -8.07% |
| 2019 Q2 | 24.83 Million SEK | 54.31% |
| 2019 Q1 | 16.09 Million SEK | -38.3% |
| 2018 Q4 | 26.09 Million SEK | 262.88% |
| 2018 Q3 | 7.19 Million SEK | 38.0% |
| 2018 Q1 | 3.6 Million SEK | -47.13% |
| 2018 FY | 42.09 Million SEK | 163.75% |
| 2018 Q2 | 5.21 Million SEK | 44.6% |
| 2017 FY | 15.96 Million SEK | 82.99% |
| 2017 Q4 | 6.81 Million SEK | 163.33% |
| 2017 Q3 | 2.58 Million SEK | -16.97% |
| 2017 Q2 | 3.11 Million SEK | 13.43% |
| 2017 Q1 | 2.74 Million SEK | 5.37% |
| 2016 Q1 | 2.34 Million SEK | 23.86% |
| 2016 FY | 8.72 Million SEK | 40.7% |
| 2016 Q3 | 1.96 Million SEK | 9.22% |
| 2016 Q2 | 1.8 Million SEK | -23.23% |
| 2016 Q4 | 2.6 Million SEK | 32.59% |
| 2015 Q1 | 1.42 Million SEK | -87.44% |
| 2015 FY | 6.19 Million SEK | 8.79% |
| 2015 Q2 | 1.45 Million SEK | 2.32% |
| 2015 Q4 | 1.89 Million SEK | 32.63% |
| 2015 Q3 | 1.42 Million SEK | -1.86% |
| 2014 Q4 | 11.32 Million SEK | 76.1% |
| 2014 Q3 | 6.42 Million SEK | 736.98% |
| 2014 FY | 5.69 Million SEK | 111.51% |
| 2014 Q2 | 767.99 Thousand SEK | 0.0% |
| 2014 Q1 | 767.99 Thousand SEK | -35.95% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 Q3 | 642 Thousand SEK | 0.0% |
| 2013 Q4 | 1.19 Million SEK | 86.76% |
| 2013 FY | 2.69 Million SEK | 81660.24% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q3 | 769.00 SEK | 0.0% |
| 2012 Q4 | 999.00 SEK | 29.91% |
| 2012 FY | 3295.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 78.768% |
| Camurus AB (publ) | 1.05 Billion SEK | 69.659% |
| Mendus AB (publ) | 129.13 Million SEK | -148.965% |
| Lipum AB (publ) | 37.3 Million SEK | -761.785% |
| NextCell Pharma AB | -576.01 Thousand SEK | 55915.173% |
| Simris Alg AB (publ) | 38.64 Million SEK | -732.012% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -1035.007% |
| Active Biotech AB (publ) | 44.8 Million SEK | -617.503% |
| Amniotics AB (publ) | 29.07 Million SEK | -1005.896% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -2094.131% |
| BioArctic AB (publ) | 89.62 Million SEK | -258.716% |
| Cantargia AB (publ) | 290.01 Million SEK | -10.858% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1368.399% |
| CombiGene AB (publ) | 44.14 Million SEK | -628.31% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -124.85% |
| Genovis AB (publ.) | 88.19 Million SEK | -264.532% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -179.393% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -4323.583% |
| Intervacc AB (publ) | 79.78 Million SEK | -302.965% |
| Kancera AB (publ) | 63.07 Million SEK | -409.704% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -5725.439% |
| LIDDS AB (publ) | 27.75 Million SEK | -1058.497% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -4332.12% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -136.555% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1921.415% |
| Saniona AB (publ) | 1.07 Million SEK | -29751.996% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 10.099% |
| Xintela AB (publ) | 57.31 Million SEK | -460.936% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -76.91% |
| Ziccum AB (publ) | 27.87 Million SEK | -1053.261% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1860.283% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -4.694% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -654.142% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1718.164% |
| Corline Biomedical AB | 30.16 Million SEK | -965.719% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -454.025% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -286.57% |
| Aptahem AB (publ) | 10.01 Million SEK | -3110.904% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -138.694% |
| Fluicell AB (publ) | 28.61 Million SEK | -1023.479% |
| Biovica International AB (publ) | 133.72 Million SEK | -140.429% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1524.588% |
| AcouSort AB (publ) | 25.87 Million SEK | -1142.487% |
| Abliva AB (publ) | 27.86 Million SEK | -1053.757% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -66.153% |
| 2cureX AB (publ) | 36.51 Million SEK | -780.404% |
| I-Tech AB | 40.14 Million SEK | -700.802% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 62.592% |
| Cyxone AB (publ) | 28.21 Million SEK | -1039.526% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -193.967% |
| Biosergen AB | 26.8 Million SEK | -1099.247% |
| Nanologica AB (publ) | 69.88 Million SEK | -360.037% |
| SynAct Pharma AB | 224.49 Million SEK | -43.212% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -627.784% |
| BioInvent International AB (publ) | 441.4 Million SEK | 27.163% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1242.166% |
| Alzinova AB (publ) | 36.39 Million SEK | -783.355% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -10.961% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -3992.35% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -189.87% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -2087.116% |